26 février 2020
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2020.16.683.0399
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32129016
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_09E60B5E42F11
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
M. Belkoniene et al., « Inhibiteurs de points de contrôle immunitaires et atteinte rénale : mise au point sur une pathologie émergente [Immune checkpoint inhibitors and renal toxicity : update about an emerging pathology] », Serveur académique Lausannois, ID : 10.53738/REVMED.2020.16.683.0399
Recently, comprehension of immune mechanisms involved in anti-tumor responses has permitted the development of new oncologic drugs called immune checkpoint inhibitors. These drugs act by restoring anti-tumor responses. With their increasing use, we note a rise in the incidence rate of immune related adverse events, which can affect many organs. Renal toxicity, more precisely tubulointerstitial nephritis, is still not well understood but an emerging complication.